42 results about "Low intraocular pressure" patented technology

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include at least two implants preloaded within a delivery device and configured to be implanted within the eye, a metering device configured to transfer energy to the implants for delivery at selected locations within the eye, wherein the metering device is configured to meter a variable amount of energy for each implant delivery event in the eye. The system can further include an injector mechanism configured to serially engage and drive each of the implants.

Systems and methods for delivering multiple ocular implants to reduce intraocular pressure are disclosed. The ocular implants can be implanted at multiple sites within a single human eye without requiring removal of the delivery apparatus from the eye. A system for delivering multiple ocular implants can include a plurality of implants, an external housing, and an introducer assembly. The external housing can provide access to an implant singulation actuator and an implant delivery actuator. The introducer assembly can comprise an auto-retracting introducer portion. The delivery apparatus can include an infinite activation mechanism / portion and / or a manual singulation mechanism / portion.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a grasping body having a longitudinal axis, and a piercing member coupled to the grasping body, including an elongate body and a beveled piercing tip including a long side and a short side, wherein the piercing member includes a proximal segment, a distal segment, and an aperture nested between the proximal segment and the distal segment, wherein the short side and the aperture are coaxially disposed along a central longitudinal axis of the piercing member, and wherein the piercing member is configured to reciprocate along the longitudinal axis relative to the grasping body.

Disclosed herein are systems, devices, kits, and associated methods for treating conditions of the eye by reducing intraocular pressure. The system may include an ocular implant and a delivery device. The ocular implant may be implantable within Schlemm's canal to restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The delivery device may include a cannula comprising a straight proximal portion and a curved distal portion, where the curved distal portion comprises a first curve in a first direction. The delivery device may also include a positioning tool positioned at least partially within the cannula and configured to advance the ocular implant through the cannula, where the positioning tool comprises a curved distal portion biased to form a second curve in a second, different direction.

Devices, methods and kits are described for reducing intraocular pressure. The devices include a support that is implantable within Schlemm's canal and that may restore or maintain at least partial patency of the canal without substantially interfering with transmural or transluminal fluid flow across the canal. The devices utilize the natural drainage process of the eye and may be implanted with minimal trauma to the eye. Kits may include a support and an introducer for implanting the support within Schlemm's canal. Methods may include implanting a support within Schlemm's canal, where the support is capable of restoring or maintaining at least partial patency of the canal without substantial interference with transmural or transluminal fluid flow across the canal.

The present disclosure relates to the treatment and / or prevention of glaucoma and other diseases affecting the optic nerve and retinal ganglion cells. In particular, the present disclosure provides novel therapeutic antibodies, and related compositions and methods, that target angiopoietin-related protein 7 (ANGPTL7) to reduce intraocular pressure (IOP) in order to prevent optic nerve damage and restore vision.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a body for grasping, a piercing member including a proximal segment and a distal segment, the distal segment including a piercing tip at a distal end thereof, and a distal stabilizer element extending from a distal end of the body, the distal stabilizer element including a lumen, wherein the piercing member is configured to reciprocate from a stored position, wherein the proximal segment is retracted within the stabilizer lumen and the piercing tip extends outwardly from the stabilizer, and an extended position, wherein the distal segment and at least a portion of the proximal segment extend outwardly from the stabilizer.

The invention discloses a magnesium alloy composite material and a preparation method and application thereof, and belongs to the technical field of magnesium alloy materials. The magnesium alloy composite material comprises a polymer and a magnesium alloy material, and the mass percentage of the magnesium alloy material in the magnesium alloy composite material does not exceed 50%. The composite material can be obtained by blending a polymer and a magnesium alloy material. The magnesium alloy composite material can be used for preparing devices or medicines for treating eye diseases, and is particularly used for preparing glaucoma drainage implantation instruments. Before magnesium alloy is degraded, the glaucoma drainage implantation instrument containing the magnesium alloy composite material is small in flow capacity, and low intraocular pressure can be prevented; after the magnesium alloy is degraded, a porous structure can be formed, so that the flow capacity of the drainage implantation instrument is increased, a normal drainage effect is achieved, and in addition, the magnesium alloy can also play a role in slowly releasing magnesium ions.

The invention relates to the technical field of medical apparatus and instruments, in particular to an intraoperative viscoelastic agent suction instrument for intraocular lens implantation, which comprises a replacement host, a liquid supply pump, a suction pump and a controller electrically connected with the liquid supply pump and the suction pump, the replacement main machine is further provided with a liquid inlet and a liquid outlet which are communicated with the liquid supply pump, and a suction port and a liquid discharge port which are communicated with the suction pump. An input connector and an output connector are arranged at one end of the handle, a replacement pipe is arranged at the other end of the handle, a liquid adding hole and a suction hole are formed in the free end of the replacement pipe, the liquid adding hole is communicated with the input connector, and the suction hole is communicated with the output connector. By balancing perfusion and suction amounts, intraoperative intraocular pressure fluctuation is avoided, intraoperative intraocular pressure caused by high intraocular pressure or intraocular pressure caused by excessive suction is avoided, and therefore the risk of optic nerve or retina injury is reduced.

A system for treating an eye comprising a tissue stored within a lumen of an elongated cannula, the tissue comprises scleral. amniotic membrane, or acellular biomatrix tissue and having an elongated form factor. Related devices, systems, and methods are provided.

This invention belongs to the field of biomedical technology, specifically relating to an engineered exosome and its applications. This invention is the first to discover that PCDH12 is specifically highly expressed in the trabecular meshwork tissue of glaucoma patients. Based on this target, engineered exosomes loaded with PCDH12 antibodies were successfully developed. These engineered exosomes can achieve non-invasive and precise targeted delivery to the trabecular meshwork tissue. In glaucoma model mouse experiments, they not only significantly reduced intraocular pressure but also effectively protected the optic nerve. The non-invasive and precise delivery strategy proposed in this invention combines potent intraocular pressure reduction with direct neuroprotection, providing a candidate solution with direct clinical translational potential for integrated "pressure reduction-neuroprotection" treatment of glaucoma.

A portable, non-invasive eye pressure monitoring device (120) comprising: a battery (106); a microscope (100) that positions the patient's eye to obtain clear scleral images for measuring eye pressure by means of sequential operations; at least one LED light (101) providing uniform illumination for taking scleral images, the intensity of which can be adjusted to avoid glare or shadows caused by uneven illumination; an objective lens (102) that focuses on the sclera by highlighting the blood vessel to ensure a sharp image; an image sensor (103) which receives the light and the magnified image of the objective lens and converts it into a digital format; a processing unit (104) which controls the processes from image acquisition to eye pressure estimation, comprising a pre-processing module (104b), a detection module (104c) and a pressure estimation module (104d), wherein the processing unit (104) finally displays the intraocular pressure to the user based on the vascular pattern via the display device.

The invention relates to a method and device for treating eye diseases, and belongs to the field of medical treatment. In order to treat ocular hypertension and glaucoma, a device for reducing intraocular pressure is provided, the device comprising: a plate having a first end and a second end, the plate comprising opposing first and second surfaces wherein the first surface comprises a series of fluid channels, the series of fluid channels are configured in an open cross-network pattern extending from a first end of the plate to a second end of the plate, the width of the first end of the plate being narrower than the width of the second end of the plate to enable the first end of the plate to be inserted into the anterior chamber of the patient, and wherein the second surface comprises a plurality of open cells formed by the fluid channels; a first coating on the first surface, the first coating conforming to a topography of the series of fluid channels, and a second coating on the second surface. The devices described herein can be used to reduce intraocular pressure and treat glaucoma.

The invention relates to the technical field of medical instruments, and provides an integrated ophthalmologic silicone oil extractor which comprises an infusion tube, the infusion tube is a hollow metal tube, the far end of the infusion tube is closed to form a blind end, an infusion opening is formed in the side wall close to the blind end, and the near end of the infusion tube is connected with a connector used for being in butt joint with an infusion apparatus; the silicone oil outflow pipe is a hollow metal pipe and is connected with the infusion pipe side by side, the far end of the silicone oil outflow pipe is a tip, and an inclined plane opening is formed in the tip; the handle is connected with the silicone oil outflow pipe, and a preset included angle is formed between the extending direction of the handle and the axial direction of the silicone oil outflow pipe. The silicone oil extractor provided by the invention can smoothly extract silicone oil through the existing incision of cataract by means of the positive pressure of water. Surgical incisions are few and do not pass through the flat part of the ciliary body, so that bleeding and detachment risks are reduced; the operation can be completed under surface anesthesia, and related hidden dangers of post-bulbous anesthesia are avoided; operation time is short, oil extraction is more thorough, normal intraocular pressure in an operation can be maintained, and complications are reduced.

Disclosed herein are methods, devices, and systems for monitoring fluid outflow behavior of an eye of a subject, for example, during ocular surgery. Changes to intraocular pressure can reflect fluid outflow behavior. Fluid outflow behavior can be a critical factor in the successful outcome of a surgery and determining likelihood of post-operative side effects. Large fluctuations in intraocular pressure, ocular hypertension, and hypotony can be associated with vision loss or poor ocular health.

The utility model discloses an eye pressure detector. The intraocular pressure detection device comprises an intraocular pressure detection structure which is used for obtaining intraocular pressure information due to extrusion after being in contact with the eyes of a user; the information transmission structure is located at one end of the intraocular pressure detection structure, the information transmission structure comprises an information processing module and a displacement measurement structure, the displacement measurement structure comprises a grating strip and a grating sensor, the grating strip is connected with the intraocular pressure detection structure, and the grating sensor is connected with the information processing module. The intraocular pressure detection structure moves to drive the grating strip to move in the sensing area of the grating sensor; the driving unit is located at one end of the information transmission structure and used for controlling the intraocular pressure detection structure to move. According to the intraocular pressure detection device, the positioning unit is arranged, a user can align the probe on the intraocular pressure detection structure with the center position of the eyes of the user through assistance of the positioning unit, the situation that the user deviates when using the intraocular pressure detection device is avoided, and errors of detected data are prevented.

The utility model belongs to the field of medical instruments, and particularly relates to a glaucoma hypertension intraocular pressure drainage device which comprises a tunnel knife used for manufacturing a sclera tunnel and an I-shaped drainage valve used for draining aqueous humor to reduce intraocular pressure, and the tunnel knife comprises a knife head and a knife handle arranged at the tail end of the knife head; a storage groove used for containing the I-shaped drainage valve is formed in the knife handle. A pipe cavity is formed in the I-shaped drainage valve in the length direction of the I-shaped drainage valve and penetrates through the I-shaped drainage valve. The tunnel knife can be used for accurately manufacturing a sclera tunnel with the length of 4mm and the width of 3mm, and the I-shaped drainage valve made of silica gel can be folded and can be implanted into the sclera tunnel through the injector. A tube cavity with the inner diameter being 60 micrometers is formed in the I-shaped drainage valve, aqueous humor can be drained to the position below the conjunctiva through the tube cavity in the drainage valve, intraocular pressure is reduced, damage of intraocular hypertension to eyes is reduced, the I-shaped drainage valve does not need to be fixed through suture, and the drainage device is simple, efficient, accurate and suitable for wide popularization.

The present invention relates to an ophthalmic aqueous composition for the decrease of intraocular pressure in patients with ocular hypertension or open angle glaucoma containing a combination of Brinzolamide and Brimonidine and a method for preparation thereof. The invention as currently presented has a significant advantage over ophthalmic compositions already known in the art. More particularly the present invention relates to a multi-dose ophthalmic aqueous composition comprising a borate, a single polyol and benzalkonium chloride as an antimicrobial agent.

The invention discloses an application of a miR-27a-3p inhibitor in preparation of a medicine for improving glaucoma. Glaucoma is a global main blinding neurodegenerative disease, retinal ganglion cell (RGC) apoptosis is a core pathological feature of the glaucoma, and existing intraocular pressure reduction treatment still cannot completely prevent neurodegenerative progress. Experiments prove that the miR-27a-3p inhibitor can be combined with 3 'UTR of PLK2 in a targeted mode, expression of the PLK2 is up-regulated, a PI3K / AKT signal channel is activated, and therefore RGC apoptosis is inhibited. A new glaucoma treatment strategy is provided, and the miR-27a-3p inhibitor can serve as an effective medicine to be used for improving glaucoma symptoms, protecting RGC and delaying disease progression and has good application prospects.

The invention belongs to the technical field of intelligent medical treatment, and relates to a biaxial intelligent intraocular pressure dynamic measurement and health management method, which comprises the following steps: preliminarily screened fused physiological signals comprise continuous intraocular pressure data and pressure state data in a synchronous time period; identifying the preliminarily screened fused physiological signals to generate an intraocular pressure event portrait representing risk causes; the intraocular pressure event portrait is analyzed to generate a comprehensive intervention file containing a coping strategy, and the comprehensive intervention file contains differentiated behavior intervention instructions; executing the comprehensive intervention file to generate real-time feedback data of intervention aftereffect; evaluating real-time feedback data of the intervention aftereffect to generate a hierarchical drug release decision; a hierarchical drug release decision is performed to generate a scaled drug release control signal. The problems that medicine waste and side effect accumulation are possibly caused when intraocular pressure is normal due to the fact that timed medicine dropping cannot be accurately matched with the actual intraocular pressure peak are solved.

The invention relates to a series of cannabinoid derivatives which can be used for reducing intraocular pressure so as to treat various diseases including glaucoma, tumors and the like.

Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications.

The present application relates to the technical field of biological medicine, and in particular to a reagent for regulating an ALKBH5-ABCA1 axis and application of the reagent in preparation of a drug for treating glaucoma, wherein the reagent at least includes any one of a reagent for promoting expression of ALKBH5, a reagent for promoting expression of ABCA1, a reagent for inhibiting expression of METTL3, and a DNA methyltransferase inhibitor for a promoter region of ALKBH5 gene.The present application provides a reagent for targeting activation of ABCA1 or a reagent for specifically targeting delivery of ALKBH5 mRNA to a trabecular meshwork, and the reagents can effectively reverse lipid metabolism defects and significantly reduce intraocular pressure.The present application not only provides a novel treatment target based on epigenetics and metabolism for glaucoma, but also realizes a proof of concept of LNP-mRNA intraocular pressure reduction technology for the first time, and has a very high clinical conversion value.

A pillow for eye pressure relief configured with a support portion and a relief portion. The support portion thicker than the relief portion. The support portion configured to support the forehead and lower face while the relief portion configured to provide less pressure and support to the facial orbital eye area.

The invention provides a suprachoroidal implant system which comprises a suprachoroidal implant and a conveyor, the suprachoroidal implant is of a porous structure and is used for being implanted into a suprachoroidal cavity, and aqueous humor is discharged from a gap between the suprachoroidal cavity and the sclera to reduce intraocular pressure; the conveyor is used for implanting a suprachoroidal cavity implant into a suprachoroidal cavity, the conveyor comprises a shell, a sheath tube assembly, an ejection piece and a pushing assembly, and the shell forms a handle part of the conveyor; the sheathing canal assembly is detachably arranged at the head end of the handle part and can store a suprachoroidal space implant; the ejection piece is fixed in the handle part along the longitudinal direction of the handle part; the ejection piece is at least partially arranged in the guide sheath tube in a penetrating manner and can act on the suprachoroidal implant; the pushing assembly is at least partially exposed out of the handle part and can act on the sheathing canal assembly to guide the guiding sheathing canal to move in the longitudinal direction of the handle part, so that the ejection piece can push the suprachoroidal cavity implant out of the guiding sheathing canal and implant the suprachoroidal cavity implant into the suprachoroidal cavity.

The invention discloses a calycosin-7-glucoside PLGA hydrogel applied to glaucoma surgery, and relates to the technical field of biological medicine, and the calycosin-7-glucoside PLGA hydrogel is prepared from the following components by weight: 1-5 parts of calycosin-7-glucoside, 20-40 parts of PLGA, 0.1-3 parts of an emulsion stabilizer, 3-8 parts of a hydrogel matrix, and 3-8 parts of a cross-linking agent. Through the construction of a dual slow-release system, the sustained release time is long, and the peak period of scar hyperplasia after operation can be covered; the semi-solid gel is attached to the sclera flap in a form, so that the adhesiveness of the surgical site is improved, and the side effects of the whole body and the secondary surgical rate can be reduced; the biocompatibility is excellent, no obvious toxicity or stimulation exists, and complications (such as low intraocular pressure and inflammation) of traditional anti-metabolic drugs can be avoided.

Surgical treatment of glaucoma involves creation of a sclerocorneal drainage channel, ensuring long-lasting controlled fluid flow and reduced intraocular pressure. Limitations relate to collateral damage to adjacent structures and outcomes being heavily reliant on the surgeon's expertise. The device described herein addresses such shortcomings. The device comprises a body for grasping, a piercing member including a proximal segment and a distal segment, the distal segment including a piercing tip at a distal end thereof, and a distal stabilizer element extending from a distal end of the body, the distal stabilizer element including a lumen, wherein the piercing member is configured to reciprocate from a stored position, wherein the proximal segment is retracted within the stabilizer lumen and the piercing tip extends outwardly from the stabilizer, and an extended position, wherein the distal segment and at least a portion of the proximal segment extend outwardly from the stabilizer.

A pillow for eye pressure relief configured with a support portion and a relief portion. The support portion thicker than the relief portion. The support portion configured to support the forehead and lower face while the relief portion configured to provide less pressure and support to the facial orbital eye area.

The utility model discloses a device capable of forming an opening in the trabecular meshwork of the eye, comprising a handle, a cutting element, a sheath tube and a pushing element, the cutting element comprises an elongated rod and two cutting blades, the tail of the elongated rod is fixedly connected with the head of the handle, and the head of the elongated rod is connected with the two cutting blades; the two cutting blades are symmetrically arranged with a predetermined opening, and the head of each cutting blade has a cutting part capable of penetrating into the trabecular meshwork and cutting the trabecular meshwork; the sheath tube is sleeved on the elongated rod and can slide along the elongated rod; the pushing element is connected with the handle and can drive the sheath tube to move towards the direction of the two cutting blades, so that the two cutting blades are closed to each other under the extrusion of the sheath tube to cut the trabecular meshwork, the cut tissue is easy to be peeled off from the trabecular meshwork, the cut part of the trabecular meshwork can form a trabecular meshwork opening, and the aqueous humor in the anterior chamber is promoted to flow out of the trabecular meshwork opening to reduce the intraocular pressure; and the size of the trabecular meshwork opening can be controlled during the cutting process.

The utility model discloses an ophthalmological pressurizing gauze, which effectively facilitates pressurizing treatment on different eyes of a patient, and comprises a fixing band and at least one piece of pressurizing cloth, the front part of the fixing band is sequentially provided with a fixing round hole and a fixing slotted hole from bottom to top, and the pressurizing cloth is positioned on the inner side of the fixing band. The pressurizing cloth sequentially comprises a contact block, a pressurizing block, a supporting block and a fixing column from back to front, a limiting mechanism is arranged on the front side of the fixing column, and the fixing column can penetrate through the fixing round hole or the fixing groove hole to be connected with the limiting mechanism. The device can be suitable for single-eye pressurization treatment and double-eye pressurization treatment, the pressure on the eyes of a patient can be adjusted at any time, operation of medical staff is facilitated, different wearing modes are added, and the device is convenient for the patient to use.